



## USO DE ANTIMICROBIANOS MEDIANTE EL GLOBAL POINT PREVALENCE SURVEY OF ANTIMICROBIAL CONSUMPTION AND RESISTANCE

**María Dolores Menéndez Fraga, Ann Versporten, Ana Fernández Blázquez, Francisco Carreño Alonso,  
Herman Goossens, Fernando Vázquez Valdés.**

Unidad de Calidad y Gestión del Riesgo Clínico, Hospital Monte Naranco, Hospital Universitario Central de Asturias,  
Faculty of Medicine and Health Sciences, Antwerp, Belgium

### Introducción:

Actualmente problema de **multirresistencia a los antimicrobianos** por lo que es necesario su **monitorización** en hospitales.

Línea prioritaria para la OMS.

El Estudio Mundial de Prevalencia de Consumo y Resistencia de Antibióticos (**Global-PPS**) permite **identificar áreas problemáticas e investigar el impacto de las medidas encaminadas a la optimización de la prescripción antibiótica.**

**Herramienta de evaluación:** La **plataforma en internet** utilizada para el registro de datos, validación y elaboración de informes, diseñada por la Universidad de Amberes, Bélgica (**[www.globalpps.com](http://www.globalpps.com)**).

### Objetivo:

**Analizar el uso de antimicrobianos y evaluar la variación en su prescripción** dentro de nuestro hospital, y para ello se **utilizó el Global-PPS** que está financiado a nivel europeo por la compañía bioMérieux.

### Material y Métodos:

**Ámbito:** **Unidad de Calidad** del Hospital Monte Naranco.

**Marco:** Hospital de 204 camas y asociado a la Universidad, fundamentalmente **pacientes agudos geriátricos y quirúrgicos.**

**Enfoque:** Proceso transversal dentro del nivel estratégico del mapa de procesos del HMN.

**Metodología:** Incluidos **todos los pacientes hospitalizados que recibieron un antimicrobiano (AM) en el día de la PPS.** Se incluyeron datos de los AM, los motivos y las indicaciones para el tratamiento, así como un conjunto de indicadores de calidad.

**Periodo:** **20 y 22 de Junio 2017.**





## RESULTADOS


### Antimicrobial prevalence in adult wards (2017)

	Total	AMW	HO-AMW	T-AMW	P-AMW	ASW	AICU
<b>Our hospital</b>							
patients (N)	111	90	0	0	0	21	0
treated patients (%)	47.7	51.1	0	0	0	33.3	0
<b>Country</b>							
patients (N)	3737	1914	101	12	149	1425	136
treated patients (%)	34.1	28	71.3	91.7	65.8	33.4	59.6
<b>Continent</b>							
patients (N)	30998	15850	1179	49	972	11284	1656
treated patients (%)	29.6	23.4	41.3	81.6	47.6	31.2	57.7
<b>Hospital type</b>							
patients (N)	17781	9996	504	0	560	5936	785
treated patients (%)	27.3	22	40.5	0	44.8	30.1	53

Patients (N) = number of admitted adults.  
Treated patients (%) = 100\*(number of adults treated with at least one antimicrobial/number of admitted adults).

Country: SPAIN ; Continent: Europe ; Hospital type: Primary or secondary hospital  
If there are less than three participating hospitals, results are not reported.

### Overall proportional antibiotic use (2017)



**56,1%**  
Penicilina/otros  
betalactámicos  
**31,6%**  
Quinolonas

Percentage of antibacterials for systemic use (ATC J01) at ATC3 level (pharmacological subgroup). Proportional antibiotic use below 0.5% is not reported.  
ICU patients refers to patients treated on an ICU department recorded with activity IC.

Country: SPAIN ; Continent: Europe ; Hospital type: Primary or secondary hospital If there are less than three participating hospitals, results are not reported.

### Therapeutic antimicrobial use for community acquired and healthcare associated infections by type of treatment (2017)

	CAI Empiric		CAI Targeted		CAI Total	
	N	%	N	%	N	%
<b>Our hospital</b>	41	83.7	8	16.3	49	94.2
<b>Country</b>	698	82.8	145	17.2	843	59.9
<b>Continent</b>	4548	78.9	1213	21.1	5761	63.7
<b>Hospital type</b>	2533	77.0	758	23.0	3291	70.9

	HAI Empiric		HAI Targeted		HAI Total	
	N	%	N	%	N	%
<b>Our hospital</b>	3	100.0	0	0.0	3	5.8
<b>Country</b>	350	62.1	214	37.9	564	40.1
<b>Continent</b>	1859	56.6	1427	43.4	3286	36.3
<b>Hospital type</b>	781	57.9	569	42.1	1350	29.1

CAI= Community Acquired Infections; HAI=Healthcare Associated Infections  
Type of treatment= empiric versus targeted treatment.  
For each subgroup of therapeutic use (CAI or HAI) the number of antimicrobials and proportion (%) for empiric versus targeted prescribing is reported.

Country: SPAIN ; Continent: Europe ; Hospital type: Primary or secondary hospital  
If there are less than three participating hospitals, results are not reported.

### Ten most common diagnoses to be treated with therapeutic antimicrobials (2017)

Diagnosis	Our hospital		Country		Continent		Hospital type	
	N	%	N	%	N	%	N	%
Pneu	32	66.7	289	26.7	1779	25.2	991	25.5
Cys	7	14.6	56	5.2	614	8.7	386	9.9
Bron	5	10.4	89	8.2	410	5.8	273	7.0
GI	1	2.1	43	4.0	293	4.1	127	3.3
Proph BJ	1	2.1	1	0.1	6	0.1	2	0.1
Pye	1	2.1	72	6.7	502	7.1	297	7.7
SST	1	2.1	132	12.2	794	11.2	443	11.4

Top ten diagnoses in our hospital. Count on the number of diagnoses treated with at least one antimicrobial.  
This implies that a patient with multiple diagnoses can be counted several times. Prophylactic prescribing and patients admitted on NICU or NMW are excluded from this analysis.

Country: SPAIN Continent: Europe Hospital type: Primary or secondary hospital  
If there are less than three participating hospitals, results are not reported.

CNS=infection of central nervous system; Eye=eye infections; ENT=ear, nose and throat infections; URTI=upper respiratory tract infection;  
Bron=bronchitis; Pneu=Pneumonia or lower respiratory tract infection; TB=tuberculosis; CVS=cardiovascular system infections;  
GI=gastro-intestinal infections; IA=intra-abdominal sepsis; SST=skin and soft tissue; BJ=bone/joint infections;  
Cys=lower urinary tract infection; Pye=Upper urinary tract infection; OBGY=obstetric/gynaecological infections;  
GUM=genito-urinary males; BAC=bacteraemia; PUO=pyrexia of unknown origin; PUO-HO=fever syndrome in non-neutropenic haematology-oncology patient; FN=fever neutropenic patient; LYMPH=infection lymphatics

**PULM 66,7%**  
**VUBJ 14,6%**  
**BRON 10,4%**

# Hospital Monte Naranco



## Summary of quality indicators for antibiotic use (2017)

### Prophylactic antimicrobial use by indication (2017)


	Medical		Surgical	
	N	%	N	%
<b>Our hospital</b>	0	0.0	5	100.0
<b>Country</b>	188	41.6	264	58.4
<b>Continent</b>	1745	43.7	2248	56.3
<b>Hospital type</b>	383	27.3	1024	72.7

Percentage of antimicrobials prescribed for medical or surgical prophylaxis. Antimicrobials include the antibacterials, antifungals and antivirals for systemic use as well as antibiotics used as intestinal anti-infectives and drugs to treat tuberculosis.

Country: SPAIN ; Continent: Europe ; Hospital type: Primary or secondary hospital  
If there are less than three participating hospitals, results are not reported.

	Hospital		Country		Continent		Hospital type	
	N	%	N	%	N	%	N	%
<b>Medical</b>								
Reason in notes	50	100.0	874	85.1	5103	82.3	2709	88.6
Guidelines missing	0	0.0	94	9.2	1032	16.6	429	14.0
Guideline compliant	46	100.0	543	73.7	3037	76.4	1828	80.9
Stop/review date documented	33	66.0	175	17.0	2238	36.1	1347	44.0
<b>Surgical</b>								
Reason in notes	7	100.0	427	69.8	3359	75.2	1739	80.1
Guidelines missing	0	0.0	45	7.4	794	17.8	265	12.2
Guideline compliant	7	100.0	317	68.6	1959	68.3	1106	69.5
Stop/review date documented	7	100.0	162	26.5	1827	40.9	1068	49.2


### Top 5 most frequently used antibiotics for pneumonia in adults and children (2017)



Selection on antibacterials for systemic use (J01). Top 5 most prescribed antibiotics (ATC5, substance level) for pneumonia at hospital level, supplemented with the most prescribed antibiotics at country, continent and hospital type level if they do not fall within the top 5 of the hospital. Selection on diagnostic code = pneu; All patients are included with exception of patients admitted on NMW and NICU.

Country: SPAIN ; Continent: Europe ; Hospital type: Primary or secondary hospital  
If there are less than three participating hospitals, results are not reported.


### Top 5 most frequently used antibiotics for surgical prophylaxis in adults and children (2017)



Top 5 most prescribed antibacterials for systemic use (ATC code J01) for surgical prophylaxis use at hospital level, supplemented with the most prescribed antibiotics at country, continent and hospital type level if they do not fall within the top 5 of the hospital. Selection on indication = SP; All patients are included with exception of patients admitted on NMW and NICU.

Country: SPAIN ; Continent: Europe ; Hospital type: Primary or secondary hospital  
If there are less than three participating hospitals, results are not reported.

# Hospital Monte Naranco



### Key prescription patterns (adults and children) (2017)

	Hospital		Country		Continent		Hospital type	
	N	%	N	%	N	%	N	%
<b>All patients</b>								
IV therapy	33	62.3	1183	83.9	7589	77.8	3685	74.4
Multiple ATB diagnosis	4	7.5	275	18.6	1811	18.0	659	13.1
Multiple ATB patient	4	7.5	320	22.7	2038	20.9	736	14.9
<b>Medical</b>								
IV therapy	26	55.3	626	73.8	8511	66.6	1768	63.7
Multiple ATB diagnosis	4	8.7	164	19.4	815	15.6	284	10.4
Multiple ATB patient	4	8.7	198	25.0	957	19.1	330	12.3
<b>Surgical</b>								
IV therapy	7	100.0	464	87.1	3083	81.1	1512	78.5
Multiple ATB diagnosis	0	0.0	76	14.4	642	17.1	271	14.4
Multiple ATB patient	0	0.0	82	15.7	690	18.6	291	15.6
<b>ICU</b>								
IV therapy	0	0.0	93	94.9	995	93.0	405	96.9
Multiple ATB diagnosis	0	0.0	35	32.7	354	31.9	104	24.2
Multiple ATB patient	0	0.0	40	41.7	391	37.7	115	27.7

Analyses at patient level. Patients admitted on a NMW and NICU are excluded.  
 Multiple ATB diagnosis is defined as receiving > 1 antibiotic (J01) for a single identified reason to treat (=diagnose code) at patient level.  
 Multiple ATB patient is defined as receiving > 1 antibiotic (J01) at patient level.

Country: SPAIN ; Continent: Europe ; Hospital type: Primary or secondary hospital  
 If there are less than three participating hospitals, results are not reported.



SERVICIO DE SALUD  
 DEL PRINCIPADO DE ASTURIAS





## Treatment based on microbiology data (2017)

	Hospital		Country		Continent		Hospital type	
	N	%	N	%	N	%	N	%
	0	0.0	0	0.0	0	0.0	0	0.0
<b>MRSA</b>	0	0.0	15	1.5	70	1.0	29	0.8
<b>MRCoNS</b>	0	0.0	17	1.7	60	0.9	13	0.3
<b>VRE</b>	0	0.0	0	0.0	10	0.1	2	0.1
<b>ESBL</b>	0	0.0	19	1.8	149	2.2	81	2.2
<b>3-ceph</b>	0	0.0	10	1.0	77	1.2	54	1.4
<b>CRE</b>	0	0.0	1	0.1	31	0.5	15	0.4
<b>ESBL-NF</b>	0	0.0	4	0.4	54	0.8	15	0.4
<b>CR-NF</b>	1	2.1	4	0.4	38	0.6	13	0.3
<b>Other MDR</b>	0	0.0	4	0.4	160	2.4	58	1.6
<b>Any of the above</b>	1	2.1	68	6.6	564	8.4	241	6.4

N = the number of patients reported to have received a microbiology-based treatment.

% = 100\*(the number of patients reported to have received a microbiology-based treatment/total number of patients receiving a therapeutic treatment (CAI or HAI) with at least one antibacterial for systemic use (J01)).

Country: SPAIN ; Continent: Europe ; Hospital type: Primary or secondary hospital  
If there are less than three participating hospitals, results are not reported.





## Conclusiones

- Mediante el **Global-PPS 2017** se han puesto en marcha medidas a través de la **Comisión Clínica de Infección Hospitalaria y Política Antibiótica** para **mejorar la adecuación de la profilaxis antibiótica del hospital** y en concreto la PAQ en cirugía traumatológica y ortopédica (>1 día de lo establecido en protocolo):
  - a) **retroalimentación** de los resultados a los profesionales implicados.
  - b) introducción en la historia clínica electrónica de un “power plan” y un **mensaje recordatorio** en la pantalla del ordenador.
  - c) **correo electrónico** de información para facultativos médicos y quirúrgicos a través de la Dirección Médica.
  - d) información Dirección y Supervisoras de Enfermería, y colocación de **cartelería** con instrucciones en las UEH.
  - e) **monitorización de indicadores** por el Servicio de Farmacia.